Compare · ANVS vs NVO
ANVS vs NVO
Side-by-side comparison of Annovis Bio Inc. (ANVS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANVS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 1723.6x ANVS ($110.9M).
- Over the past year, ANVS is down 38.4% and NVO is down 45.6% - ANVS leads by 7.3 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 7 for ANVS).
- NVO has more recent analyst coverage (25 ratings vs 4 for ANVS).
- Company
- Annovis Bio Inc.
- Novo Nordisk A/S
- Price
- $1.73-1.99%
- $42.79+1.42%
- Market cap
- $110.9M
- $191.15B
- 1M return
- -28.42%
- -7.76%
- 1Y return
- -38.39%
- -45.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2020
- News (4w)
- 7
- 8
- Recent ratings
- 4
- 25
Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANVS
- Annovis Bio Regains NYSE Listing Compliance
- Director Hoffman Michael B bought $142,779 worth of shares (76,344 units at $1.87), increasing direct ownership by 2% to 3,364,883 units (SEC Form 4)
- Annovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 424B5 filed by Annovis Bio Inc.
- Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
- SEC Form 424B5 filed by Annovis Bio Inc.
- Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
- SEC Form 10-Q filed by Annovis Bio Inc.
- Annovis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care